IDT Australia
- Company typePublic
- Founded1974
- HeadquartersBoronia, Australia
- Headcount101–250
- GTM typeB2B
- OfferingServices
IDT Australia firmographics
Firmographics- Name
- IDT Australia
- Legal name
- IDT Australia
- Website
- https://en.idtaus.com.au
- Company type
- Public
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
IDT Australia industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
Keywords
Where IDT Australia is headquartered
LocationHeadquarters
- HQ city
- Boronia
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
IDT Australia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Contract Manufacturing Services: Contract development and manufacturing organization (CDMO) providing fee-for-service pharmaceutical development and manufacturing solutions across pre-clinical, clinical, and commercial stages.
- Regulatory Services: Regulatory support services enabling pharmaceutical partners to commercialize products with FDA, TGA, and APVMA regulatory approvals.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based custom pricing for pharmaceutical development and manufacturing services |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
IDT Australia product offering
Product offeringCore offering
IDT Australia is a Contract Development and Manufacturing Organization (CDMO) that produces active pharmaceutical ingredients (APIs), formulates specialty oral dosage forms including Schedule 8 and 9 controlled drugs, and manufactures advanced therapies such as sterile fill-finish products, lyophilised injectables, mRNA therapeutics, and radiopharmaceuticals. Services span pre-clinical through commercial stages and include R&D, analytical and microbiological testing, ICH stability testing, labelling and packaging, project management, supply chain and distribution, and regulatory support.
Product overview
IDT Australia operates as a Contract Development and Manufacturing Organization (CDMO) offering end-to-end cGMP pharmaceutical manufacturing solutions. The portfolio comprises Active Pharmaceutical Ingredients (APIs) services including small molecule and cytotoxic compound manufacturing, Specialty Orals covering tablets, capsules, and liquid formulations, and Advanced Therapies including Sterile Fill and Finish, mRNA, and Radiopharma services. These core capabilities are supported by Integrated Services encompassing R&D, analytical testing, ICH stability testing, labelling and packaging, project management, supply chain, and regulatory support. The company trades on ASX under ticker IDT:IDT.
Differentiator
Problem solved
Functional benefit
Products and services
- Active Pharmaceutical Ingredients (APIs) Contract development and manufacturing of small molecule APIs, including highly potent and cytotoxic compounds, from pre-clinical through commercial scale, plus linker-payload manufacturing for antibody-drug conjugates (ADCs). Offered to pharmaceutical and biotech partners requiring cGMP API supply.
- Specialty Orals Contract formulation and production of solid oral dosage forms including tablets and capsules, non-sterile liquid products, and Schedule 8 and Schedule 9 controlled drug products. Offered to pharmaceutical and biotech partners requiring cGMP oral solid dose manufacturing.
- Sterile Fill and Finish Advanced sterile manufacturing service providing aseptic fill and finish of injectable medicines into vials, supporting partners requiring cGMP sterile injectable production.
- Radiopharma Manufacturing Contract radiopharmaceutical manufacturing service for diagnostic and therapeutic applications, available to advanced therapy developers needing specialised radiopharma production.
- mRNA Manufacturing Services Contract manufacturing capability for mRNA-based therapeutics and vaccines, provided to pharmaceutical and biotech clients developing mRNA medicines.
- Advanced Therapies Manufacturing Integrated advanced therapy manufacturing service combining advanced sterile fill and finish into vials, lyophilisation (freeze-drying), and radiopharmaceutical manufacturing for partners developing advanced therapeutic products.
- Integrated Services End-to-end CDMO support services covering Research and Development, Analytical and Microbiological testing, ICH Stability testing, Labelling and Packaging, Project Management, Supply Chain and Distribution, and Regulatory support for pharmaceutical and biotech clients across pre-clinical, clinical, and commercial stages.
Quantifiable outcome
- R&D Tax Incentive offering up to 43.5% refundable cash benefit for eligible projects
Companies that use IDT Australia
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
IDT Australia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
IDT Australia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Gelteq LimitedcoreGelteq Limited has partnered with IDT Australia through a memorandum of understanding to establish a dedicated, locally-based manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. The partnership leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise, including FDA, TGA, and APVMA regulatory capabilities, to support Gelteq's product scale-up. The agreement aims to accelerate product development and enable rapid expansion of manufacturing capacity for global markets.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
IDT Australia competitors and assessment
Company assessmentDirect peers
- Corden Pharma: Full-service CDMO with strong capabilities in highly potent APIs, peptide manufacturing, and sterile fill-finish — closely comparable to IDT's cytotoxic, ADC linker-payload, and controlled-substance specialisations.
- Recipharm: European CDMO focused on small-molecule API manufacturing, sterile fill-finish, and oral dosage forms — directly overlapping with IDT's core service portfolio across multiple modalities.
- PCI Pharma Services: Global CDMO providing integrated clinical and commercial manufacturing, packaging, and supply chain services. Comparable in the integrated CDMO plus packaging/labelling positioning that IDT markets.
- AGC Biologics: Global biopharmaceutical CDMO with capabilities across microbial and mammalian biologics, as well as gene therapy and fill-finish. Comparable as a contract manufacturer serving pharma and biotech developers with cGMP capabilities.
- Catalent: One of the largest global CDMOs offering integrated development, manufacturing, and packaging across small molecules, biologics, and advanced therapies. Directly comparable to IDT in end-to-end CDMO positioning, though at substantially greater scale.
- Lonza Group: Swiss-based global CDMO leader with capabilities spanning APIs (small and large molecule), fill-finish, and advanced therapies. Comparable business model and customer base to IDT, but with global multi-site capacity that IDT cannot match.
- Bora Pharmaceuticals: Asia-Pacific-focused CDMO with capabilities in small-molecule oral solids, sterile injectables, and complex formulations. Comparable as a mid-sized, regionally anchored CDMO competing for similar contract manufacturing work as IDT.
Emerging players
- Syneos Health: Contract research and manufacturing organisation providing clinical development and commercial services to biopharma. Partial overlap with IDT through its clinical-stage manufacturing and packaging service line.
Broad incumbents
- Thermo Fisher Scientific (Patheon): Through its Patheon business, Thermo Fisher offers one of the broadest CDMO service portfolios globally. Operates broadly across drug substance, drug product, and clinical services — overlapping significantly with IDT but as part of a much larger life sciences platform.
Regional players
- Mayne Pharma: Australian-headquartered specialty pharmaceutical company with capabilities in complex oral and injectable generics manufacturing. Comparable regional CDMO/manufacturing exposure serving similar therapeutic categories to IDT within the Australian market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
IDT Australia social profiles
Digital presenceIDT Australia compliance and trust
Trust signalCompliance4 records
IDT Australia financial estimates
Financial estimateRevenue estimate
Valuation estimate
IDT Australia leadership team
Management profileNumber of profiles
IDT Australia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IDT Australia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IDT Australia
What does IDT Australia do?
IDT Australia is a Contract Development and Manufacturing Organization (CDMO) that produces active pharmaceutical ingredients (APIs), formulates specialty oral dosage forms including Schedule 8 and 9 controlled drugs, and manufactures advanced therapies such as sterile fill-finish products, lyophilised injectables, mRNA therapeutics, and radiopharmaceuticals. Services span pre-clinical through commercial stages and include R&D, analytical and microbiological testing, ICH stability testing, labelling and packaging, project management, supply chain and distribution, and regulatory support.
Is IDT Australia a public or private company?
IDT Australia is a public company. It is classified as public and is currently operating.
When was IDT Australia founded?
IDT Australia was founded in 1974. It employs 101 to 250 people.
Where is IDT Australia based?
IDT Australia is headquartered in Boronia, Australia, in the Oceania region.
How does IDT Australia make money?
Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are regulatory Services.
Who are IDT Australia's main competitors?
Direct peers on record are Corden Pharma, Recipharm, PCI Pharma Services, AGC Biologics, Catalent, Lonza Group and Bora Pharmaceuticals. Syneos Health is listed as an emerging player. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent. Mayne Pharma is listed as a regional player.
Does IDT Australia have an API?
No public API is recorded for IDT Australia.
What industry is IDT Australia in?
IDT Australia's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325412 and its SIC code is 2834.